Table 4.
Breast cancer-specific mortality associated with the ER/PR/HER2 score
| ER/PR/HER2 score a | Number of women | Number of deaths |
Adjusted HR (95% CI) |
|
|---|---|---|---|---|
| Model 1 b | Model 2 c | |||
|
Women with ER-negative invasive breast cancer |
|
|||
| Overall |
|
|
|
|
| < 0 |
60 |
15 |
Referent |
Referent |
| 0 |
337 |
103 |
1.32 (0.76 to 2.32) |
1.30 (0.74 to 2.28) |
| > 0 |
109 |
39 |
1.43 (0.77 to 2.69) |
1.43 (0.76 to 2.67) |
| Trend |
|
|
Ptrend = 0.30 |
Ptrend = 0.29 |
| White women |
|
|
|
|
| < 0 |
35 |
9 |
Referent |
Referent |
| 0 |
162 |
46 |
1.20 (0.55 to 2.62) |
1.09 (0.48 to 2.45) |
| > 0 |
54 |
14 |
1.16 (0.46 to 2.90) |
1.09 (0.43 to 2.76) |
| Trend |
|
|
Ptrend = 0.79 |
Ptrend = 0.88 |
| Black women |
|
|
|
|
| < 0 |
25 |
6 |
Referent |
Referent |
| 0 |
175 |
57 |
1.46 (0.59 to 3.61) |
1.47 (0.60 to 3.64) |
| > 0 |
55 |
25 |
1.57 (0.61 to 4.06) |
1.55 (0.60 to 4.03) |
| Trend |
|
|
Ptrend = 0.42 |
Ptrend = 0.45 |
|
Homogeneity of trends between white women and black women |
Phomogeneity = 0.36 |
Phomogeneity = 0.32 |
||
|
Women with ER-positive invasive breast cancer | ||||
| Quartiles of ER/PR/HER2 scored |
|
|
|
|
| Overall |
|
|
|
|
| Q1 |
175 |
18 |
Referent |
Referent |
| Q2 |
177 |
22 |
1.27 (0.65 to 2.45) |
1.39 (0.71 to 2.70) |
| Q3 |
172 |
33 |
2.04 (1.10 to 3.81) |
2.00 (1.07 to 3.76) |
| Q4 |
174 |
42 |
2.71 (1.48 to 4.95) |
2.48 (1.36 to 4.55) |
| Trend |
|
|
Ptrend = 0.0002 |
Ptrend = 0.001 |
| White women |
|
|
|
|
| Q1 |
118 |
9 |
Referent |
Referent |
| Q2 |
105 |
10 |
1.41 (0.53 to 3.74) |
1.37 (0.52 to 3.62) |
| Q3 |
113 |
20 |
2.03 (0.84 to 4.92) |
1.98 (0.82 to 4.78) |
| Q4 |
94 |
23 |
2.77 (1.19 to 6.45) |
2.62 (1.12 to 6.11) |
| Trend |
|
|
Ptrend = 0.01 |
Ptrend = 0.01 |
| Black women |
|
|
|
|
| Q1 |
57 |
9 |
Referent |
Referent |
| Q2 |
72 |
12 |
1.32 (0.50 to 3.51) |
1.60 (0.58 to 4.45) |
| Q3 |
59 |
13 |
2.34 (0.85 to 6.42) |
2.34 (0.83 to 6.55) |
| Q4 |
80 |
19 |
3.43 (1.33 to 8.84) |
2.88 (1.08 to 7.67) |
| Trend |
|
|
Ptrend = 0.006 |
Ptrend = 0.03 |
| Homogeneity of trends between white women and black women | Phomogeneity = 0.56 | Phomogeneity = 0.32 | ||
CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; PR, progesterone receptor.
aER/PR/HER2 score = 94.7 × (–0.100 ER10 – 0.079 PR10 + 0.586 HER2); the range of ER/PR/HER2 scores was –71.07 to 55.49 in women with ER-negative tumor and –141.10 to 53.92 in women with ER-positive tumor.
bMultivariable Cox proportional hazards regression models using age (in days) as the time metric stratified by age (in years) and adjusted for race (white, black), study site (Detroit, Los Angeles), tumor stage (localized, non-localized).
cAdditionally adjusted for histologic grade (low, intermediate, high); low and intermediate were combined into a single category in analyses for women with ER-negative tumors due to a small number of women with a low grade.
dQuartiles of ER/PR/HER2 scores in all women with ER-positive tumors were Q1 (–141.10 to –97.33), Q2 (–97.32 to –68.98), Q3 (–68.97 to –36.66), and Q4 (–36.65 to 53.92).